Enhancement of radioiodine uptake in hyperthyroidism with hydrochlorothiazide: a prospective randomised control study.
The aim of this study was to determine whether hydrochlorothiazide (HCTZ) could improve radioiodine uptake in low-uptake hyperthyroid patients. Eighteen hyperthyroid patients with low 3-h and 24-h iodine-131 uptake were recruited to the study. Eleven patients were assigned to the HCTZ group, and seven to the control group. Two weeks after the first, baseline uptake study, a second uptake study was performed. Patients in both groups had a low-iodine diet after the first uptake study. In the HCTZ group, 50 mg of HCTZ was administered twice a day for 5 days prior to the second uptake study. Improvement in uptake at 3 and 24 h in the second uptake study, as compared with the baseline study, was assessed within and between groups. In the control group, compared with the baseline study there was a significant improvement in uptake at 3 h ( P=0.03) but a non-significant improvement at 24 h ( P=0.07). In the HCTZ group, significant improvements were observed at both 3 h ( P=0.0005) and 24 h ( P=2.28 x 10(-5)). Patients in the HCTZ group had statistically greater improvement in uptake at both 3 h and 24 h compared with the control group ( P=0.003 and 0.0008, respectively). There was a 7.18-fold average improvement in uptake in the HCTZ group at 24 h, compared with only a 1.33-fold improvement in the control group. Administration of HCTZ significantly improves 24-h radioiodine uptake in high-iodide pool, low-uptake hyperthyroid patients compared with patients who have received a low-iodine diet alone.
Tepmongkol
Supatporn
S
Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. supatporn@hotmail.com
D000328:Adult; D017024:Chemotherapy, Adjuvant / Q000379:methods; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage*; D006980:Hyperthyroidism / Q000188:drug therapy* / Q000378:metabolism* / Q000532:radiotherapy; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use; D012680:Sensitivity and Specificity
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D006852:Hydrochlorothiazide